Carbogen breathing increases prostate cancer oxygenation: a translational MRI study in murine xenografts and humans

Hypoxia has been associated with poor local tumour control and relapse in many cancer sites, including carcinoma of the prostate. This translational study tests whether breathing carbogen gas improves the oxygenation of human prostate carcinoma xenografts in mice and in human patients with prostate cancer. A total of 23 DU145 tumour-bearing mice, 17 PC3 tumour-bearing mice and 17 human patients with prostate cancer were investigated. Intrinsic susceptibility-weighted MRI was performed before and during a period of carbogen gas breathing. Quantitative R 2 * pixel maps were produced for each tumour and at each time point and changes in R 2 * induced by carbogen were determined. There was a mean reduction in R 2 * of 6.4% ( P =0.003) for DU145 xenografts and 5.8% ( P =0.007) for PC3 xenografts. In all, 14 human subjects were evaluable; 64% had reductions in tumour R 2 * during carbogen inhalation with a mean reduction of 21.6% ( P =0.0005). Decreases in prostate tumour R 2 * in both animal models and human patients as a result of carbogen inhalation suggests the presence of significant hypoxia. The finding that carbogen gas breathing improves prostate tumour oxygenation provides a rationale for testing the radiosensitising effects of combining carbogen gas breathing with radiotherapy in prostate cancer patients.